FDA Authorizes 30 Nicotine Pouches: How the Pilot Program Is Reshaping the US Oral Tobacco Market in 2026

FDA’s nicotine pouch pilot program has accelerated regulatory approvals, with 30 products now authorized for sale in the US market.

The US Food and Drug Administration has authorized 30 nicotine pouch products as of August 2026, marking a significant milestone in the regulation of oral tobacco alternatives. This expansion, driven by Altria subsidiary Helix Innovations’ latest four-product authorization, signals a fundamental shift in how the FDA approaches smokeless nicotine products. For industry stakeholders, the question is no longer whether nicotine pouches will gain mainstream acceptance, but how quickly the market will fragment among competing brands.

The FDA’s nicotine pouch Pilot Program: From Testing to Mainstream

The FDA launched its nicotine pouch pilot program in September 2025 to streamline the Premarket Tobacco Application (PMTA) pathway. The program introduced real-time communication between regulators and applicants, reducing the time needed to address deficiency letters and accelerating scientific reviews. By August 2026, this approach has become the standard operating procedure for all nicotine pouch PMTAs.

According to the FDA’s August 4 announcement, the latest four authorized products—Rich Berry 2 mg, Cappuccino 2 mg, Cappuccino 4 mg, and Autumn Spice 2 mg—were manufactured by Helix Innovations LLC under the “on!” brand. The agency’s scientific review found these products contained significantly lower levels of harmful and potentially harmful constituents (HPHCs) compared to traditional oral tobacco products.

The FDA’s pilot program has established a new regulatory pathway for oral tobacco alternatives.

Regulatory Concentration: PMI and Altria Dominate

As of August 2026, all 30 FDA-authorized nicotine pouch products come from subsidiaries of Philip Morris International (PMI) or Altria Group. This concentration highlights the significant barriers to entry in the regulated US oral tobacco market. PMI’s Swedish Match USA produces 20 ZYN products, while Altria’s Helix Innovations manufactures 10 on!/on! PLUS variants.

Market Data: The $5.7B Oral Nicotine Revolution

The US nicotine pouch market has experienced explosive growth, with volume increasing 23% year-over-year and value growing 14% in Q2 2026. According to industry data, nicotine pouches now represent 59.9% of the oral tobacco category, up 8.1 percentage points from a year ago. This shift represents one of the most significant structural changes in the tobacco industry since the introduction of e-cigarettes.

The oral nicotine category is experiencing rapid growth as consumers shift from combustible and smokeless tobacco.

Competitive Landscape: The Velo Challenge

While ZYN remains the market leader, British American Tobacco’s Velo Plus has emerged as the fastest-growing brand. Velo’s US market share surged from 7.3% in December 2024 to 31.0% in May 2026, capturing approximately 90% of the category’s value growth during this period. BAT’s aggressive pricing strategy—offering Velo Plus at a 46.5% discount to MSRP—has accelerated consumer adoption.

“The oral nicotine category is undergoing a fundamental transformation. With 30 FDA-authorized products and competition intensifying between PMI, Altria, and BAT, we’re seeing the emergence of a mature, regulated market that could reshape the entire tobacco landscape.” — Industry Analyst, Tobacco Insider

Consumer Migration Patterns

PMI’s internal data reveals that 45% of ZYN users switched from cigarettes, 33% from e-cigarettes, and 22% from traditional oral tobacco products. The convenience factor—no hands required, indoor-friendly, no secondhand smoke—drives adoption. Notably, youth uptake remains low at 5.4% compared to 22.1% for e-cigarettes, a key factor in the FDA’s favorable regulatory approach.

Stock Market Impact: Tobacco Giants in Flux

The FDA’s nicotine pouch authorization expansion has created divergent outcomes for major tobacco stocks. Altria (MO) shares reacted modestly to the on! authorization, while PMI’s ZYN dominance faces growing competitive pressure from BAT’s Velo expansion.

Tobacco stocks are responding to regulatory developments and competitive dynamics in the oral nicotine market.

Supply Chain Implications: OEM Opportunities

The expansion of FDA-authorized nicotine pouches creates opportunities across the supply chain. Contract manufacturers, nicotine salt suppliers, and packaging companies stand to benefit from increasing production volumes. However, the market concentration among PMI and Altria suggests that securing contracts with these major players is critical for growth.

Manufacturing Considerations

Nicotine pouch production requires specialized equipment and expertise in tobacco-free nicotine delivery systems. The shift toward higher nicotine strengths (12mg products) and diverse flavor profiles demands flexible manufacturing capabilities. Companies like Swedish Match, Helix Innovations, and emerging contract manufacturers are investing in production capacity to meet growing demand.

“The FDA’s streamlined review process has removed a significant bottleneck for the oral nicotine category. With 30 products now authorized and the pilot program’s practices becoming standard, we expect to see an acceleration of product submissions and market expansion.” — Regulatory Affairs Specialist

Global Market Context: Beyond the US

The US market represents only a fraction of the global nicotine pouch opportunity. In Sweden, nicotine pouch penetration approaches 66% among adult males, demonstrating the category’s potential in mature markets. European adoption is growing rapidly, with BAT reporting 65% volume share in its main AME markets.

International expansion opportunities are emerging in South Africa (LOOP brand launch), South Korea (regulatory framework development), and Southeast Asia (growing interest from tobacco companies). The global oral nicotine market is projected to reach EUR 15 billion by 2028, with a compound annual growth rate of 25%.

Global expansion of nicotine pouches extends beyond the US market to Europe, Asia, and emerging regions.

Closing Outlook: Three Strategic Moves for Industry Stakeholders

The FDA’s authorization of 30 nicotine pouch products marks a pivotal moment in the oral tobacco market’s evolution. For manufacturers, retailers, and investors, three strategic priorities emerge: